Skip to main content Accessibility help

Descriptive Evaluation of a Smoking Cessation Support Service for Chronic Disease Clients Within a Hospital Admissions Risk Program

  • Pam Shields (a1), Robyn Bradley (a1), Marnie Graco (a2) and A. Hutchinson (a2)


Introduction: The Northern Alliance HARP smoking cessation program provides support to chronic disease participants who desired to quit smoking. This is an individualised program with pharmacotherapy and behavioural support, delivered by specialist clinicians.

Aims: The aims of this descriptive evaluation were to explore factors that affect abstinence rates, record those rates, and describe the impact of anxiety, depression, self-efficacy, quality of life and motivation on quit rates at three months.

Methods: Data was collected prospectively from clients enrolled in the service. Participants were assessed for abstinence at three months, six months and one year by carbon monoxide (CO) monitoring and self-reporting. Factors predictive of quitting were analysed using logistic regression; factors with a p value < 0.05 and 95% CI not containing one were considered statistically significant.

Results: 103 clients were assessed and 86 were enrolled in the program. The odds of successful quitting at three months CO verified was higher amongst completers of the program compared to non-completers (OR = 6.6, 95% CI = 2.03–21.57, p = 0.002). The probability of sustained quitting at one year was over 18 times higher in the group who completed the program (n = 16/21 completers and n = 1/4 non-completers) (OR 18.5, 95% CI, 2.32–147.34, p = 0.006). No other factors predicted quitting.

The rate of quitting was 28.7% at three months, 19.5% at six months and 10.3% at one year, CO verified. Measures of anxiety and depression, self-efficacy, quality of life and motivation did not influence either the quit rate or the likelihood of completing the course of treatment at three months.


Corresponding author

Address for correspondence: Pam Shields, BN, B Psych (Hons), Respiratory Nurse Consultant/Smoking Cessation Facilitator Northern HARP Alliance, Melbourne Victoria, Australia. Email:


Hide All
Andersson, C. L. (2001). The New York Heart Association (NYHA) Functional Classification in a Patientwith Heart Disease. Retrieved april 8, 2014, from
Anthonisen, N. (1997). Epidemiology and the lung health study. European Respiratory Review, 7 (45), 202205.
Anthonisen, N. R., Connect, J. E., & Murray, R. P. (2002). Smoking and lung function of lung health study participants after 11 years. American Journal Respiratory Critical care Medicine, 166, 675679. doi:10.1164/rccm.2112096
Aubin, H., Bobak, A., Britton, J. R., Oncken, C., Billing, C., Gong, J. Jr. et al. (2008). Varenicline verses Transdermal nicotine patch for smoking cessation: Results from a randomised, open- label trial. Thoraxonline. Retrieved from
Benowitz, N. (2009). Pharmacology of nicotine addiction smoking induced disease and therapeutics. Annual Review of Pharmacology and Oxology, 49, 5771. doi:10.1146/annurev.pharmtox.48.113006.094742
Benowitz, N., Jacob, P., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J. et al. (2002). Biochemical verification of tobacco use and cessation. Nicotine and Tobacco Research, 4, 149159. doi:10.1080/14622200210123581
Berlowitz, D. J. & Graco, M. (2010). The development of a streamlined, coordinated and sustainable evaluation methodology for a diverse chronic disease management program. Australian Health Review, 34 (2), 148151.
Beyondblue (2013). Beyond Blue depression and anxiety older people. Retrieved august 1st, 2013, from Beyond Blue depression and anxiety:
Bittoun, R. (2005). Smoking Cessation Workshop Course Notes. Lung Health Promotion Centre at the Alfred. September 2005. 1–40.
Bittoun, R. (2006). A Combination Nicotine replacement Therapy (NRT) Algorithm for Hard-to-treat smokers. Journal of Smoking Cessation, 1 (1), 36.
Bittoun, R. (2007). The ‘treatment-resistant’ smoker. Medicine Today, 8 (8), 1625.
Bittoun, R. (2008). Carbon monoxide meter: The essential clinical tool-the “Stethoscope”-of smoking cessation. Journal of Smoking Cessation 3 (2), 6970.
Brandt, C. J., Ellegaard, H., Joensen, M., Kallan, F. V., Sorknaes, A. D., & Tougaard, L. (1997). Effect of diagnosing” smokers lung”. The Lancet, 349, 253.
Buckley, C., O’Dowd, D., Gannon, K., & Brennan, M. (2006). A naturalistic study of an Australian smoking cessation model in a victorian community health service with 12-month follow-up. Journal of Smoking Cessation, 2 (2), 5458.
Burton, S. M. & Tiffany, S. T. (1997). The effect of alcohol consumption on craving to smoke. Addiction, 92 (1), 1526.
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013). Pharmacological interventions for smoking cessation: An overview and network meta-analysis. The Cochrane Library, 5. CD009329. doi:10.1002/14651858.CD009329.pub2
Chapman, S., & McKenzie, R. (2010). The global research neglect of unassisted smoking cessation: Causes and consequences. PLOS Medicine, 7 (2), 16.
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., . . . O'Neill, B. T. (2005). Varenicline: An alpha 4 Beta 2 nicotinic receptor partial agonist for smoking cessation. Journal of Medical Chemistry, 48 (10), 34743477.
Dawson, G. W. & Vestal, R. E. (1981). Smoking and drug metabolism. Pharmocology and Theraputics, 15, 207221.
Fagerstrom, K. O., Kunze, M., Schoberberger, R., Breslau, N., Hughes, J. R., . . . Zatonski, W. (1996). Nicotine dependence verses smoking prevelence: Comparisons among countries and categories of smokers. Tobacco Control, 5, 5256. doi:10.1136/tc.5.1.52
Ferguson, J. B. (2005). The English smoking treatment service:one year utcomes. Addiction, 100 (2), 5962.
Ferguson, S. G., Shiffman, S., & Gitchell, J. G. (2011). Nicotine replacement therapies; patient outcome and safety. Patient Related Outcome Measures, 2, 111117. doi:10.2147/PROM.S11545
Fiore, M., & Baker, T. (2011). Treating smokers in the health care setting. The New England Journal of Medicine, 365 (13), 12221231.
Galbraith, L. (2010). NHS Smoking Cessation service statistics (Scotland). 1st January to 31st December 2009.
Gellert, C., Schottker, B., & Brenner, H. (2012). Smoking and all-cause mortality in older people: systematic review and meta-analysis. Archives of Internal Medicine, 172 (11), 837844. doi:10.1001/archinternmed.2012.1397
Global Initiative for Chronic Obstructive Pulmonary Disease (2011). Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. Available from:
Heatherton, T. K. (1991). The fagerstrom test for nicotine dependence: A revision of the fagerstrom tolerance questionnaire. British Journal of Addictions, 86 (11), 1927.
Ischaki, E., & Gratziou, C. (2009). Smoking and depression: Is smoking cessation effective? Therapeutic Advances in Respiratory Disease, 3 (1), 3138.
Khan, M., & Richardson, J. (2010). Smoking Status and Quality of life: Preliminary results from a sample of Adult Smokers who called Quitline. Melbourne: Monash University.
McLeod, S. (2007). Pavlov's Dogs. Retrieved august 18, 2014, from
McLeod, S. (2007). Skinner-Operant Conditioning. Retrieved august 18, 2014, from
McKenzie, D. K., Frith, P. A., Burdon, J. G. W, & Town, G. I (2011). The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003. MJA 2003 178(6 Suppl 17 Mar), S1–S40.
Mendelsohn, C. (2011). Nicotine dependence: Why is it so hard to quit? Medicine Today 12 (10), 3539.
Miller, W. R., & Rollnick, S. (2002). Motivational Interviewing Preparing People for Change 2nd edn. London, New York: The Guilford Press.
NICE (2014). Guidelines for smoking cessation. Retrieved from NICE:, 6th Aug, 2014.
Piper, M. S. (2009). A randomised placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Archives of General Psychiatry, 66 (11), 12531262.
Richardson, J., Khan, M. A., Ghen, G. & Iezzi, A. (2012). Population norms and Australian profile using the Assessment of Quality of Life (AQoL) 8D utility instrument. Melbourne: Monash University.
Schwarzer, R., & Jerusalem, M. (1995). Generalized self-efficacy scale. In Weinman, J., Wright, S. (Eds.), Measures in health psychology: A user's portfolio. Causal and control beliefs (pp. 3537). Windsor England: NFER-NELSON.
The Department of Human Services (2004). Hospital Admission Risk Program. Retrieved:
Tonnesen, P., Carrozzi, L., Fagerstrom, K. O., Gratziou, C., Jimenez-Ruiz, C., Nardini, S. et al. (2007). Smoking cessation in patients with respiratory diseases: A high priority, integral component of therapy. European Respiratory Journal, 29 (2), 390417.
Tonnessen, P. (2009). Smoking cessation: How compelling is the evidence? A review. Science Direct Health Policy Supplement 1, s15s25.
West, R. (2004). ABC of smoking cessation: Assessment of dependence and motivation to stop smoking. British Medical Journal, 328, 338339. doi:
Windsor, UK: NFER-NELSON (2008). Smoking cessation services in primary care, pharmacies, local authorities and work places particularly for manual working groups, pregnant women and hard to reach communities. (2008, Feb). Retrieved from
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361370. doi:10.1111/j.1600-0447.1983.tb09716.x
Zwar, N. (2008). Smoking cessation what works? Australian Family Physician, 37 (1/2), 1014.
Zwar, N., Richmond, R., Borland, R., Peters, M., Litt, J., Bell, J. et al. (2011). Supporting Smoking Cessation: A Guide for Health Professionals. Melbourne: The Royal Australian College of General Practitioners.

Descriptive Evaluation of a Smoking Cessation Support Service for Chronic Disease Clients Within a Hospital Admissions Risk Program

  • Pam Shields (a1), Robyn Bradley (a1), Marnie Graco (a2) and A. Hutchinson (a2)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed